So this goes right after the guidelines. In prostate cancer, one of the biggest issues is heterogeneity. You have tumor cells that are very AR-dependent right next to tumor cells that can diverge, undergo lineage plasticity through epigenetic reprogramming, transform into neuroendocrine prostate cancer, for example. One of those main mediators is EZH2, which is a polycomb repressor complex that regulates cell differentiation and AR signaling...
So this goes right after the guidelines. In prostate cancer, one of the biggest issues is heterogeneity. You have tumor cells that are very AR-dependent right next to tumor cells that can diverge, undergo lineage plasticity through epigenetic reprogramming, transform into neuroendocrine prostate cancer, for example. One of those main mediators is EZH2, which is a polycomb repressor complex that regulates cell differentiation and AR signaling. So the TulmiSTAR-01 trial is attempting to combine an AR degrader to target the AR positive cells with an epigenetic agent, an EZH2 inhibitor, all oral, to try to prevent or delay radiographic progression in patients that have metastatic androgen pathway resistant disease. And this is a phase one slash two study. It’s dose finding, followed by dose expansion, followed by randomization. So it’s a very large global trial. We have a trial in progress poster that talks about the endpoints and the layout and the clinical trial design.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
